Immunogen (IMGN) Misses Q1 on Top and Bottom
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Price: $31.25 --0%
Financial Fact:
Research and development: 32.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Research and development: 32.91M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Immunogen (NASDAQ: IMGN) reported Q1 EPS of ($0.26), $0.11 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $21.8 million.
For earnings history and earnings-related data on Immunogen (IMGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phoenix Education Partners (PXED) PT Lowered to $32 at Jefferies
- Red Rock Resorts (RRR) PT Lowered to $60 at StoneX
- Datadog shares drop on weak Q4 revenue outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
